Agomab Therapeutics NV (AGMB) SEC 13F Holdings (Q2 2026) — Net Institutional Activity: $41.3M

AGMB ranks #7186 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

AGMB is a top-conviction position for Andera Partners — at 9.7% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in AGMB belongs to EQT Fund Management S.a r.l., but the position matters far more to Andera Partners, who has 9.7% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

AGMB is down 0.6% today, but institutions show net buying of $41.3M this quarter — a divergence between today's price move and the underlying institutional flow.

AGMB reported a net loss of $62.5M in its latest fiscal year.

• Not yet profitable — net loss of $62.5M in the latest fiscal year
• Net income declined year over year, from -$46.3M to -$62.5M
• Operating cash flow was negative, using $51.7M in cash
• Current ratio of 6.52x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.17x equity — within a conventional range